- **Galera Therapeutics** has entered into an Asset Purchase Agreement with Toronto-based **Biossil Inc.** for its dismutase mimetics portfolio, including avasopasem and rucosopasem.  **[1563577_25997295825e43bf92897470c04f2701_0]** 
- The agreement includes an **upfront payment of $3.5 million** and potential future regulatory and commercial milestones, and contingent value rights of up to **$105 million** in aggregate.  **[1563577_25997295825e43bf92897470c04f2701_0]** 
- Biossil will assume all obligations for a **4% royalty** to Blackstone Life Sciences should the dismutase mimetics products reach commercialization.  **[1563577_25997295825e43bf92897470c04f2701_0]** 
- Following this transaction, Galera's lead program will be its pan-inhibitor of Nitric Oxide Synthase (NOS), currently in a multicenter Phase 2 trial for metaplastic breast cancer.  **[1563577_25997295825e43bf92897470c04f2701_0]** **[1563577_25997295825e43bf92897470c04f2701_1]** 
- Avasopasem, part of the acquired portfolio, had previously received FDA **Fast Track and Breakthrough Therapy designations** and showed a statistically significant reduction in severe oral mucositis in a Phase 3 trial.  **[1563577_25997295825e43bf92897470c04f2701_0]** **[1563577_25997295825e43bf92897470c04f2701_1]**

Galera Therapeutics (GRTX)